Clinical and Translational Core

项目摘要/摘要：临床与翻译核心(CTC) 斯坦福临床与翻译核心(CTC)的目标是通过以下方式促进高影响力的糖尿病研究 发改委委员。在斯坦福大学，不同科学领域的尖端技术的先驱们经常在 寻找与人类受试者合作的临床合作者，以将他们的发现‘转化’到临床上。同样，临床 研究人员往往因为缺乏对改进或新事物的认识或接触而未能创新 方法论。此外，试图翻译他们的工作的科学家和临床医生团队经常遇到 监管程序、招聘/留住、样本管理和深思熟虑的数据收集方面的障碍， 导致时间利用效率低下、样本丢失、无法完成研究以及提供银行服务的积极性降低 供合作者参考的样本。反恐中心将通过利用现有的斯坦福大学来满足这些具体需求 专注于针对糖尿病的研究的资源，从而增强我们机构进行创新的能力 超越单一研究人员/实验室能力的高影响跨学科研究。一个在线的 调查显示，76%的发改委调查人员打算使用CTC。 CTC将由一个董事团队领导，该团队在各自的糖尿病相关研究领域处于国家领先地位： 加德纳、麦克劳克林和德赛博士。反恐委员会将开发和提供三项核心服务：1)a) 现有的和预期收集的样本的生物信息库，并使收集和样本标准化 跟踪和链接到临床数据，所有这些都可以通过一个集中的中心访问；2)分析方面的高级支持 包括研究设计、数据库设计和在RedCap中设置数据捕获以及与电子产品的链接 医疗记录和生物存储库、数据管理和数据分析，以及3)临床试验支持 包括建立临床登记以进行招募，并指导试验的后勤和进行， 以及最大化保留率和合规性。4)反恐委员会将指导国家发改委调查人员及其 并培训他们有效地使用这些核心服务。 反恐委员会将提供设计研究的创新方法和计算机系统， 记录数据，记录样本，并将样本结果与表型和代谢数据联系起来。斯坦福大学 CTC将利用在校园内开发的科学方法和研究支持系统方面的专业知识，但 未得到充分利用或尚未针对糖尿病研究量身定做。在整个机构范围内支持协作和 “团队”科学、数据收集方法现代化和资源共享。国家发改委对CTC的使用情况 成员将推进协调、协作和沟通的规划、执行和沟通 变革性的临床和转化性研究。

Project Summary / Abstract: Clinical & Translational Core (CTC) The goal of the Stanford Clinical & Translational Core (CTC) is to facilitate high-impact diabetes research by SDRC members. At Stanford, pioneers in cutting-edge technologies of diverse science fields are often in search of clinical collaborators with human subjects to `translate' their findings to the clinic. Similarly, clinical investigators often fail to innovate based on a lack of awareness or accessibility to improved or novel methodologies. In addition, teams of scientists and clinicians attempting to translate their work often encounter hurdles with regulatory processes, recruitment/retention, sample management, and thoughtful data collection, leading to inefficient use of time, sample loss, failure to complete studies, and disincentive to provide banked samples for collaborators. The CTC will address these specific needs by leveraging existing Stanford resources to focus on diabetes-specific research, thus enhancing our institution's ability to perform innovative high-impact interdisciplinary studies that surpass the capabilities of a single investigator/laboratory. An online survey revealed that 76% of SDRC investigators intend to use the CTC. The CTC will be led by a team of directors that are national leaders in their fields of diabetes-related research: Drs. Gardner, McLaughlin and Desai. The CTC will develop and provide three core services: 1) A biorepository of existing and prospectively collected samples with standardization of collection and sample tracking, and links to clinical data, all accessible via a centralized hub; 2) Advanced support in analytics including study design, database design with setup of data capture in REDCap and linkage to the electronic medical record and biorepository, data management, and data analysis, and 3) Clinical trial support that includes the creation of a Clinical Registry for recruitment, and guidance in the logistics and conduct of trials, as well as for maximizing retention and compliance. 4) The CTC will orient SDRC investigators and their teams and train them to use each of these core services effectively. The CTC will provide access to innovative methodologies and computer-based systems for designing studies, recording data, logging samples, and linking sample results to phenotypic and metabolic data. The Stanford CTC will leverage expertise in scientific methods and research-support systems developed on campus but that are underused or not yet tailored to diabetes research. Institution-wide support exists for collaborative and “team” science, for modernizing data collection methods, and for resource sharing. Use of the CTC by SDRC members will advance the planning, execution and communication of coordinated, collaborative, and transformative clinical and translational research.